Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Recommendation of “Buy” by Analysts

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has been given a consensus rating of “Buy” by the twelve ratings firms that are covering the firm, MarketBeat Ratings reports. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $32.70.

CNTA has been the subject of several analyst reports. Truist Financial initiated coverage on shares of Centessa Pharmaceuticals in a research note on Monday, July 21st. They issued a “buy” rating and a $30.00 price objective for the company. Wall Street Zen downgraded shares of Centessa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 16th. Lifesci Capital raised shares of Centessa Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, September 3rd. Needham & Company LLC started coverage on shares of Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They set a “buy” rating and a $35.00 price target for the company. Finally, Wells Fargo & Company started coverage on shares of Centessa Pharmaceuticals in a research note on Wednesday, September 3rd. They set an “overweight” rating and a $31.00 price target for the company.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Wednesday, June 25th. The shares were sold at an average price of $13.86, for a total transaction of $138,600.00. Following the transaction, the insider directly owned 122,279 shares of the company’s stock, valued at $1,694,786.94. This trade represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel Iqbal J. Hussain sold 12,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $14.02, for a total transaction of $168,240.00. Following the transaction, the general counsel directly owned 105,386 shares in the company, valued at approximately $1,477,511.72. The trade was a 10.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 171,322 shares of company stock valued at $2,472,814. 7.09% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in Centessa Pharmaceuticals by 1,509.6% in the first quarter. GAMMA Investing LLC now owns 61,762 shares of the company’s stock worth $888,000 after purchasing an additional 57,925 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth $162,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth $171,000. Cutter Capital Management LP lifted its stake in shares of Centessa Pharmaceuticals by 184.3% during the first quarter. Cutter Capital Management LP now owns 418,127 shares of the company’s stock worth $6,013,000 after buying an additional 271,051 shares during the period. Finally, Cerity Partners LLC acquired a new stake in shares of Centessa Pharmaceuticals during the first quarter worth $471,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Trading Up 8.9%

CNTA opened at $22.71 on Thursday. The company has a current ratio of 10.11, a quick ratio of 10.12 and a debt-to-equity ratio of 0.32. The firm has a market cap of $3.04 billion, a P/E ratio of -12.69 and a beta of 1.47. Centessa Pharmaceuticals has a 12 month low of $9.60 and a 12 month high of $22.95. The stock has a 50-day moving average of $16.42 and a 200 day moving average of $14.54.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.03). As a group, research analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.